talimogene laherparepvec

11/01/2015 - "For example, the most recent phase III trial data on a herpes simplex virus (HSV)-based oncolytic virus (T-VEC) show substantial improvement in objective and durable responses over the control arm in melanoma patients, prompting speculation that a virotherapy may receive FDA approval for clinical use in the very near future. "
05/01/2020 - "Here, we describe the usage of T-VEC in stage IVM1b-M1c melanoma patients, who achieved complete remission or stable disease upon systemic treatment but suffered from a loco-regional recurrence. "
02/01/2017 - "T-VEC demonstrated significant improvement in durable response rate, objective response rate, and progression-free survival in a randomized phase III clinical trial for patients with advanced melanoma. "
08/01/2017 - "Clinical trials have confirmed the safety and efficacy of T-VEC as monotherapy for the treatment of advanced melanoma, with an overall response rate (ORR) of 26%. "
12/01/2018 - "T-VEC leads the way with improved survival outcomes for unresectable, stage IIIB-IVM1a melanoma as a monotherapy, and is demonstrating superior results in combination with systemic checkpoint inhibitors. "

01/31/2023 - "With proven efficacy, T-VEC has been evaluated against a variety of other cancer types in a clinical trial setting. "
01/01/2023 - "A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors."
01/01/2022 - "This case demonstrates for the first time the feasibility of this innovative add-on immunovirotherapy regimen with a profound, repetitive and durable replication of T-VEC that is instrumental in achieving tumor stabilization and improvement in the patient´s quality of life. "
01/01/2023 - "The safety data were consistent with the patients' underlying cancer and the known safety profile of T-VEC from studies in the adult population. "
01/01/2023 - "An expanding body of data on the clinical experience of patients receiving T-VEC is now becoming available as are data from clinical trials of various other OVs in a range of other cancers. "

01/01/2023 - "In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU/ml; ≤4 ml) was administered into hepatic lesions via image-guided injection every 21 (±3) days. "
01/01/2023 - "We suggest the combination of T-VEC and MEKi as an off-label treatment option for patients with NRAS mutations, especially with recurrent in-transit or satellite metastases."
12/01/2022 - "Metastases with a pink pattern harboured glomerular and arborizing vessels that diminished and vanished during treatment T-VEC, indicating CR. "
12/01/2022 - "Macroscopic and dermoscopic pictures of these metastases were taken at baseline, prior to each treatment with T-VEC and prior to histological biopsy. "
07/01/2022 - "All 5 patients that were re-treated with T-VEC presented with in-transit metastases on the lower limb. "

01/01/2021 - "Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial."
01/01/2020 - "Pembrolizumab with the oncolytic virus talimogene laherparepvec was effective in treating sarcomas."
01/01/2020 - "Talimogene Laherparepvec plus Pembrolizumab Is Effective in Sarcomas."
01/01/2020 - "In this phase 2 clinical trial, treatment with T-VEC plus pembrolizumab was associated with antitumor activity in advanced sarcoma across a range of sarcoma histologic subtypes, with a manageable safety profile. "
01/01/2020 - "Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial."

11/15/2021 - "We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. "
11/15/2021 - "A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer."
01/01/2023 - "The primary objective was to evaluate the safety and adverse event profile of immunotherapy combined with T-VEC in patients with localized, HER2-negative breast cancer. "
08/01/2020 - "SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer."
08/01/2020 - "SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negative breast cancer who present residual disease after neoadjuvant chemotherapy. "